Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Keeping Track: Neurology And Breakthroughs Stay In Spotlight As US FDA Approves Radicava, Imfinzi; TaiMed Submits Ibalizumab
Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK
Agile's Phase III Data For Twirla Patch Fall Flat, Raise Doubts On Approval
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros
Keeping Track: Gazyva, Afinitor Get New Indications; PTC's Translarna Gets Refuse To File
Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel
Agile SEC filing reveals FDA rejection for Twirla contraceptive

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel